LepiDyne

Seoul, South Korea Founded: 2019 • Age: 7 yrs
Developer of liquid biopsy test kits for cancer detection
Annual revenue - Latest available
Total funding - Funding intelligence
Employees - Tracked headcount
Investors - Known backers
Products 4 Services tracked
Competitors 10 Brand Intelligence

About LepiDyne

LepiDyne is a company based in Seoul (South Korea) founded in 2019. LepiDyne offers products and services including MethyLiverDx, MethyLiverPro, MethyLiverMT, and LepiMag. LepiDyne operates in a competitive market with competitors including Guardant Health, Natera, Foundation Medicine, ArcherDX and Strand Life Sciences, among others.

  • Headquarter Seoul, South Korea
  • Sectors
    Healthcare
  • Email
    Locked
  • Phone
    Locked
  • Website
    Locked
  • Legal Name (주)레피다인
  • Jurisdiction Na, Maharashtra, India
Operational Areas
Healthcare → Healthcare Products & Supplies Unlock Sub-Sector Unlock Segment
Key Metrics
  • Annual Revenue
    Not available
  • Net Profit
    Not available
  • EBITDA
    Not available
  • Latest Funding Round
    Not available
  • Investors
    Not available
  • Employee Count
    Not available
Upgrade to premium

Unlock complete access to The Company Check

Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.

Upgrade to Premium No viewing limits. Your plan controls exports and screening usage.
Included in your Premium account
  • Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
  • Full access to every database India & global coverage, advanced filters and rich profile details
  • Always-on access from your team account Single premium plan for everything you see on the portal

Products & Services of LepiDyne

LepiDyne offers a comprehensive portfolio of products and services, including MethyLiverDx, MethyLiverPro, MethyLiverMT, and LepiMag.

Product name locked
Category locked
Primary

Kit for early blood-based diagnosis of liver cancer

Product name locked
Category locked
Locked

Kit for predicting liver cancer treatment outcomes

Product name locked
Category locked
Locked

Kit for monitoring liver cancer treatment progress

Product name locked
Category locked
Locked

Kit for extracting cell-free DNA from blood samples

Funding Insights of LepiDyne

Premium access

Detailed funding history for LepiDyne

Round names, dates, amounts, investors, and valuation history require an active premium plan.

  • Round names and dates
  • Funding amounts
  • Participating investors
  • Valuation history

Verified entity values are shown only after access is granted.

Investments & Acquisitions by LepiDyne

Investments
Premium access

Investment portfolio details for LepiDyne

Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.

  • Portfolio identities
  • Transaction dates
  • Round details
  • Investment values

Verified entity values are shown only after access is granted.

Financial Statements - LepiDyne

Premium access

Detailed financials for LepiDyne

Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.

  • Historical revenue
  • Profit trends
  • Statement rows
  • Financial ratios

Verified entity values are shown only after access is granted.

Lepidyne Comparisons

LepiDyne Primary company
Description
Developer of liquid biopsy test kits for cancer detection
Location
Seoul, South Korea
Founded Year
2019
Annual Revenue
Not available
Net Profit
Not available
EBITDA
Not available
Employees
Not available
Premium access

Peer comparison for LepiDyne

Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.

  • Named peers
  • Headcount comparison
  • Funding comparison
  • Operating benchmarks

Verified entity values are shown only after access is granted.

+
Add Comparison
Available on Premium

Competitors of LepiDyne

LepiDyne operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Guardant Health, Natera, Foundation Medicine, ArcherDX and Strand Life Sciences, among others.

Company Name Domain Founded year HQ Location Description
Locked Locked Locked
Digital sequencing technology for cancer detection is developed.
Locked Locked Locked
Developer of cell-free DNA testing for oncology, women’s health, and organ health
Locked Locked Locked
Genomics-based diagnostic tests for cancer are provided.
Locked Locked Locked
Molecular cancer diagnostic products are developed using patented AMP technology.
Locked Locked Locked
Provider of omics-based solutions for clinical genomics, systems biology, and drug discovery
Locked Locked Locked
Health risks are identified through online genetic and diagnostic testing.
Premium access

Detailed competitors of LepiDyne

Competitor domains, locations, full profiles, and operating metrics require an active premium plan.

  • Domains and locations
  • Full company profiles
  • Operating metrics
  • Competitive positioning

Verified entity values are shown only after access is granted.

Latest news on Lepidyne

Premium access

Complete news archive for LepiDyne

Full article history, source details, and older brand coverage require an active premium plan.

  • Full article archive
  • Source and publication date
  • Older coverage
  • Brand-specific news history

Verified entity values are shown only after access is granted.

Frequently Asked Questions about LepiDyne

LepiDyne was founded in 2019.

LepiDyne is headquartered in Seoul, South Korea.

Young Joon Kim is the current CEO of LepiDyne.

LepiDyne was founded in 2019 in Seoul, South Korea, where tumor-specific DNA methylation markers in blood are discovered, developed, and clinically validated for cancer detection. Operations center on liquid biopsy technologies within the biotechnology sector. Key products, including MethyLiverDx, MethyLiverPro, and MethyLiverMT, are offered for liver cancer diagnostics. Leadership is provided by CEO Young Joon Kim, with activities based in South Korea.

LepiDyne's top competitors include Guardant Health, Strand Life Sciences and Foundation Medicine.

LepiDyne offers MethyLiverDx, MethyLiverPro, MethyLiverMT, and LepiMag.

Explore millions of companies — effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals — all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available